Advertisement
Singapore markets closed

  • Straits Times Index

    3,331.70
    +5.42 (+0.16%)
     

  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     

  • Dow

    39,112.16
    -299.05 (-0.76%)
     

  • Nasdaq

    17,717.65
    +220.84 (+1.26%)
     

  • Bitcoin USD

    61,358.66
    +254.24 (+0.42%)
     

  • CMC Crypto 200

    1,275.39
    -8.40 (-0.65%)
     

  • FTSE 100

    8,219.52
    -28.27 (-0.34%)
     

  • Gold

    2,328.20
    -2.60 (-0.11%)
     

  • Crude Oil

    81.28
    +0.45 (+0.56%)
     

  • 10-Yr Bond

    4.2880
    +0.0500 (+1.18%)
     

  • Nikkei

    39,667.07
    +493.92 (+1.26%)
     

  • Hang Seng

    18,089.93
    +17.03 (+0.09%)
     

  • FTSE Bursa Malaysia

    1,590.95
    +5.57 (+0.35%)
     

  • Jakarta Composite Index

    6,905.64
    +22.94 (+0.33%)
     

  • PSE Index

    6,313.11
    +14.06 (+0.22%)
     

Gyros Protein Technologies Introduces Gyrolab Generic Anti-AAV Kit to Support Gene Therapy Development

Business Wire
·1-min read

Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays

UPPSALA, Sweden, June 17, 2024--(BUSINESS WIRE)--Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers today announced the introduction of its Gyrolab® Generic Anti-Adeno Associated Virus (AAV) Kit. The new ready-to-use kit facilitates the qualitative assessment of pre-existing binding antibodies against AAV vectors, enabling screening in pre-clinical and clinical settings. The kit supports identification of pre-existing immunity that may interfere with the efficacy of AAV-based gene therapy delivery.

The ready-to-use kit, designed to detect total binding anti-capsid antibodies against the most commonly used AAV serotypes, is the first of its kind on the market for assessing pre-existing anti-AAV antibodies, streamlining the screening process by eliminating the need for serotype-specific assay development. Compared to other methods currently used for detecting pre-existing binding antibodies, the kit removes the need for capsid labelling, reducing variability and ensuring reproducible data whilst requiring small quantities of viral capsids, preserving precious drug volumes.

ADVERTISEMENT

The kit is optimized for use on all Gyrolab systems and expands the utility of the Gyrolab platform into the bioanalytical field of AAV-based gene therapies. Automation with Gyrolab systems reduces variability due to manual pipetting and speeds up workflows by reducing assay development time and generating results within 90 minutes, helping to accelerate the development of novel gene therapies.

Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: "The new Gyrolab Generic Anti-AAV Kit is tailored to meet customer needs in the bioanalysis of AAV-based gene therapeutics, focusing on efficiency, resource, and time-savings. This innovative addition expands our portfolio of ready-to-use kits, providing a rapid, cost-effective solution for the detection of total binding antibodies without necessitating serotype-specific assay development or extensive optimization. Gyrolab Generic Anti-AAV Kit provides our customers with convenience whilst ensuring robust and reliable data. This allows for more informed decisions regarding individual stratification following preexisting anti-AAV antibody screening."

For more information on the Gyrolab Generic Anti-AAV Kit, please visit:
https://www.gyrosproteintechnologies.com/immunoassays/products/gyrolab-generic-anti-aav-kit

View source version on businesswire.com: https://www.businesswire.com/news/home/20240617414845/en/

Contacts

Dr Ben Rutter
Zyme Communications:
Tel: +44 (0) 7920 770 935
Email: ben.rutter@zymecommunications.com